Nanotechnology as a tool to overcome macromolecules delivery issues

• Published in: Colloids and surfaces, B, Biointerfaces Vol. 222; p. 113043
• Main Authors: Tundisi, Louise Lacalendola, Ataide, Janaína Artem, Costa, Juliana Souza Ribeiro, Coêlho, Diego de Freitas, Liszbinski, Raquel Bester, Lopes, André Moreni, Oliveira-Nascimento, Laura, de Jesus, Marcelo Bispo, Jozala, Angela Faustino, Ehrhardt, Carsten, Mazzola, Priscila Gava
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.02.2023
• Subjects: Drug Delivery Systems; Humans; Macromolecular Substances; Macromolecule; Nanomedicine; Nanoparticles - chemistry; Nanotechnology; Nanotoxicity; Pharmaceutical Preparations - chemistry; Proteins; Regulation; Nanotoxicity; Drug delivery systems; Regulation; Macromolecule; Nanotechnology
• ISSN: 0927-7765; 1873-4367
• DOI: 10.1016/j.colsurfb.2022.113043

Nanocarriers can deliver drugs to specific organs or cells, potentially bridging the gap between a drug’s function and its interaction with biological systems such as human physiology. The untapped potential of nanotechnology stems from its ability to manipulate materials, allowing control over physical and chemical properties and overcoming drug-related problems, e.g., poor solubility or poor bioavailability. For example, most protein drugs are administered parenterally, each with challenges and peculiarities. Some problems faced by bioengineered macromolecule drugs leading to poor bioavailability are short biological half-life, large size and high molecular weight, low permeability through biological membranes, and structural instability. Nanotechnology emerges as a promising strategy to overcome these problems. Nevertheless, the delivery system should be carefully chosen considering loading efficiency, physicochemical properties, production conditions, toxicity, and regulations. Moving from the bench to the bedside is still one of the major bottlenecks in nanomedicine, and toxicological issues are the greatest challenges to overcome. This review provides an overview of biotech drug delivery approaches, associated nanotechnology novelty, toxicological issues, and regulations. [Display omitted] •Nanotechnology still has an untapped potential.•Macromolecules are administered parenterally, each with challenges and uniqueness.•Nanotechnology is a promising strategy to overcome macromolecules delivery issues.•Nanocarriers should be carefully chosen, considering loading efficiency and toxicity.•Nanotechnology has been well accepted as strategy to deliver macromolecules.